Last reviewed · How we verify

Zirconium Zr 89-DFO-YS5

Robert Flavell, MD, PhD · Phase 1 active Small molecule

Zirconium Zr 89-DFO-YS5 is a Small molecule drug developed by Robert Flavell, MD, PhD. It is currently in Phase 1 development. Also known as: (89)Zr-DFO-YS5, 89Zr DFO-YS5.

At a glance

Generic nameZirconium Zr 89-DFO-YS5
Also known as(89)Zr-DFO-YS5, 89Zr DFO-YS5
SponsorRobert Flavell, MD, PhD
ModalitySmall molecule
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Zirconium Zr 89-DFO-YS5

What is Zirconium Zr 89-DFO-YS5?

Zirconium Zr 89-DFO-YS5 is a Small molecule drug developed by Robert Flavell, MD, PhD.

Who makes Zirconium Zr 89-DFO-YS5?

Zirconium Zr 89-DFO-YS5 is developed by Robert Flavell, MD, PhD (see full Robert Flavell, MD, PhD pipeline at /company/robert-flavell-md-phd).

Is Zirconium Zr 89-DFO-YS5 also known as anything else?

Zirconium Zr 89-DFO-YS5 is also known as (89)Zr-DFO-YS5, 89Zr DFO-YS5.

What development phase is Zirconium Zr 89-DFO-YS5 in?

Zirconium Zr 89-DFO-YS5 is in Phase 1.

Related